Silvia Pescina

Prof. Dr. Silvia Pescina

Department of Food and Drug, University of Parma, 43124 Parma, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Fabio SonvicoFabio Sonvico
Fabio Sonvico
ACAdryana Clementino
Adryana Clementino
Francesca ButtiniFrancesca Buttini
Francesca Buttini
GCGaia Colombo
Gaia Colombo
Silvia PescinaSilvia Pescina
Silvia Pescina
Sara NicoliSara Nicoli
Sara Nicoli
In the field of nasal drug delivery, nose-to-brain delivery is among the most fascinating applications, directly targeting the central nervous system, bypassing the blood brain barrier. Its benefits include dose lowering and direct brain distribution of potent drugs, ultimately reducing systemic side effects. Recently, nasal administration of insulin showed promising results in clinical trials for the treatment of Alzheimer’s disease. Nanomedicines could further contribute to making nose-to-brain delivery a reality. While not disregarding the need for devices enabling a formulation deposition in the nose’s upper part, surface modification of nanomedicines appears the key strategy to optimize drug delivery from the nasal cavity to the brain. In this review, nanomedicine delivery based on particle engineering exploiting surface electrostatic charges, mucoadhesive polymers, or chemical moieties targeting the nasal epithelium will be discussed and critically evaluated in relation to nose-to-brain delivery.

24 January 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
MGMaria Aurora Grimaudo
Maria Aurora Grimaudo
Silvia PescinaSilvia Pescina
Silvia Pescina
CPCristina Padula
Cristina Padula
PSPatrizia Santi
Patrizia Santi
ACAngel Concheiro
Angel Concheiro
Sara NicoliSara Nicoli
Sara Nicoli

1 August 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
Silvia PescinaSilvia Pescina
Silvia Pescina
COCarmine Ostacolo
Carmine Ostacolo
IGI.M. Gomez-Monterrey
I.M. Gomez-Monterrey
MSM. Sala
M. Sala
ABA. Bertamino
A. Bertamino
Sara NicoliSara Nicoli
Sara Nicoli

3 April 2019 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
MGMaria Aurora Grimaudo
Maria Aurora Grimaudo
Silvia PescinaSilvia Pescina
Silvia Pescina
CPCristina Padula
Cristina Padula
PSPatrizia Santi
Patrizia Santi
ACAngel Concheiro
Angel Concheiro
Sara NicoliSara Nicoli
Sara Nicoli
Introduction: Polymeric micelles represent nowadays an interesting formulative approach for ocular drug delivery, as they act as solubility enhancers of poorly soluble drugs and promote drug transport across cornea and sclera. In particular, in the last 5 years polymeric nanomicelles have been increasingly investigated to overcome some of the important challenges of the topical treatment of ocular diseases. Areas covered: The aim of this review was to gather up-to-date information on the different roles that polymeric micelles (commonly in the nano-size scale) can play in ocular delivery. Thus, after a general description of ocular barriers and micelles features, the attention is focused on those properties that are relevant for ophthalmic application. Finally, their efficacy in improving the ocular delivery of different classes of therapeutics (anti-inflammatory, immunosuppresant, anti-glaucoma, antifungal, antiviral drugs) are reported. Expert opinion: Although still a few, in vivo experiments have clearly demonstrated the capability of polymeric nanomicelles to overcome a variety of hurdles associated to ocular therapy, notably increasing drug bioavailability. However, there are still some very important issues to be solved, such as tolerability and stability; additionally, the role of micelles in drug uptake by the ocular tissues and their potential for the treatment of posterior eye diseases still need to be clarified/verified.

1 July 2018 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
MBMarta Benigni
Marta Benigni
Silvia PescinaSilvia Pescina
Silvia Pescina
MGMaria Aurora Grimaudo
Maria Aurora Grimaudo
CPCristina Padula
Cristina Padula
PSPatrizia Santi
Patrizia Santi
Sara NicoliSara Nicoli
Sara Nicoli

26 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Felipe M González-FernándezFelipe M González-Fernández
Felipe M González-Fernández
Annalisa BiancheraAnnalisa Bianchera
Annalisa Bianchera
PGPaolo Gasco
Paolo Gasco
Sara NicoliSara Nicoli
Sara Nicoli
Silvia PescinaSilvia Pescina
Silvia Pescina
Nanotherapeutics based on biocompatible lipid matrices allow for enhanced solubility of poorly soluble compounds in the treatment of ophthalmic diseases, overcoming the anatomical and physiological barriers present in the eye, which, despite the ease of access, remains strongly protected. Micro-/nanoemulsions, solid lipid nanoparticles (SLN) or nanostructured lipid carriers (NLC) combine liquid and/or solid lipids with surfactants, improving drug stability and ocular bioavailability. Current research and development approaches based on try-and-error methodologies are unable to easily fine-tune nanoparticle populations in order to overcome the numerous constraints of ocular administration routes, which is believed to hamper easy approval from regulatory agencies for these systems. The predictable quality and specifications of the product can be achieved through quality-by-design (QbD) implementation in both research and industrial environments, in contrast to the current quality-by-testing (QbT) framework. Mathematical modelling of the expected final nanoparticle characteristics by variation of operator-controllable variables of the process can be achieved through adequate statistical design-of-experiments (DoE) application. This multivariate approach allows for optimisation of drug delivery platforms, reducing research costs and time, while maximising the understanding of the production process. This review aims to highlight the latest efforts in implementing the design of experiments to produce optimised lipid-based nanocarriers intended for ophthalmic administration. A useful background and an overview of the different possible approaches are presented, serving as a starting point to introduce the design of experiments in current nanoparticle research.